Abstract 1416P
Background
Infusion-related reaction (IRR) are a common toxicty of amivantamab, with a high incidence during the first infusion (97%). However, subsequent injections are usually not affected, unless there is a delay in treatment for several weeks. We evaluate the risk of IRR after the resumption of amivantamab, based on the duration of the free treatment interval.
Methods
This was a retrospective observational study to evaluate the recurrence of IRR in advanced non-small cell lung cancer patients treated with amivantamab and lazertinib in Gustave Roussy (2019-2023).
Results
Baseline characteristics of patients are summarized in the table. 24 patients were included, 12 (50%) presented IRR during the first infusion, and only one of them presented previous history of allergy. 9 patients had a temporary discontinuation of treatment, but only 2 had an IRR recurrence (these 2 had experienced an IRR during first cycle). Median time of treatment discontinuation was of 25.57 days for those patients without IRR recurrence and 44 days for those who presented it. Both patients with IRR recurrence had a temporary withdrawal due to another toxicity (at day 29 and 59 respectively) being of CTCAE grade 3 and 2 respectively. 5 patients (41.6%) needed corticoesteroids and 6 (50%) received antihistamines as treatment for the IRR. Only one patient required magnesium sulfate. A third IRR recurrence was experienced in both patients (grade 2 and 1 respectively), leading to permanent treatment discontinuation for one patient. None of the patients progressed to amivantamab and both are still alive. Table: 1416P
Gender (N) Female Male | 15 9 |
Median age, Years (IQR) | 66 (39-81) |
Molecular profile (N) EGFR exon 19 EGFR exon 20 EGFR L858R MET overexpression MET exon 14 skipping mutation | 11 1 9 1 2 |
Median number of previous lines (IQR) | 2 |
Conclusions
Recurrence of IRR after the first episode is frequent and must be taken into account when reintroducing amivantamab after a temporary withdrawal of ≥1 month. IRR recurrence does not seem to have a detrimental impact on treatment efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. A. Gazzah: Non-Financial Interests, Advisory Board: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche; Financial Interests, Advisory Board: Novartis, Sanofi , Roche, Pfizer, Novartis, Boehringer Ingelheim; Financial Interests, Principal Investigator: Amgen, Astex, Argen-X Byba, Bristol Myer Squibb, Celegne, Gilead, Lilly, Novartis, Pharma Mar, Pierre Fabre, Merck Sharp. P. Lavaud: Financial Interests, Advisory Board: Astellas, AstraZeneca, Janssen, Sanofi; Non-Financial Interests, Advisory Board: AstraZeneca, Hoffman-La Roche; Other: Astellas. A. Levy: Financial Interests, Institutional, Invited Speaker: Pharma Mar; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Coordinating PI: BeiGene. S. Ponce Aix: Financial Interests, Advisory Board: BMS, MSD, Roche, AstraZeneca, Takeda. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Eisai, Genzyme Corporation, Inivata, Ipsen, Turning Point Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20